Get the Daily Brief
Latest Biotech News
Zealand posts Phase 2 win: amylin analog yields up to 10.7% mean
Zealand Pharma released Phase 2 data for petrelintide, an amylin analog that drew one of the industry’s largest obesity partnerships last year. The company reported mean weight reductions up to...
Lilly offers employer program — study finds GLP‑1 weight regain plateaus below baseline
Eli Lilly launched a program aimed at expanding employer coverage of GLP‑1 obesity medicines while new meta‑analysis data show weight regain after GLP‑1 receptor agonists tends to plateau below...
Moderna to pay up to $2.25B — settlement narrows LNP patent risk
Moderna agreed to settle long‑running patent litigation over lipid nanoparticle (LNP) delivery technology, committing to up to $2.25 billion under terms that include a $950 million upfront...
PepGen hit with FDA partial hold — U.S. trial enrollment paused
The FDA placed a partial clinical hold on PepGen’s Freedom2 Phase 2 trial for PGN‑EDODM1, a therapy for myotonic dystrophy type 1 (DM1), citing questions about previously submitted preclinical...
Atavistik boosts Series B to $160M — advances HHT clinical program
Atavistik Bio announced a $40 million extension to its Series B, bringing total Series B financing to $160 million to support clinical development of its lead allosteric programs, including a...
Dravet gene therapy posts dramatic seizure reductions in early trials
Clinical results for zorevunersen, a one‑time gene regulation therapy for Dravet syndrome, showed substantial seizure reductions in pediatric patients and improved functional outcomes, according...
Cell‑free chromatin tracing maps tissue origins: cf‑EpiTracing goes automated
Researchers at Peking University unveiled cf‑EpiTracing, an automated cell‑free DNA approach that profiles chromatin marks to infer tissue and cell‑type origins of disease from plasma. Published...
Liquid biopsy moves beyond cancer: cfDNA fragmentomics spots liver disease
Johns Hopkins investigators and collaborators reported that genome‑wide cell‑free DNA fragmentomics can detect liver fibrosis and cirrhosis by identifying organ‑specific fragmentation patterns and...
UCB enters T‑cell engager field: $1.1B deal for Antengene’s ATG‑201
UCB struck a licensing agreement with Antengene to acquire worldwide rights to ATG‑201, a CD19×CD3 bispecific T‑cell engager (TCE) for autoimmune disease, in a deal with up to $1.1 billion in...
Liquid biopsy moves beyond cancer: cfDNA epigenomics detects liver disease
Researchers published two independent advances this week that broaden the scope of liquid biopsy from oncology into chronic liver disease. Peking University teams described cf‑EpiTracing, an...
Moderna to pay up to $2.25B: LNP patent settlement ends long‑running suit
Moderna reached a landmark settlement with Arbutus Biopharma and Roivant’s Genevant unit over lipid nanoparticle (LNP) delivery patents, agreeing to an upfront cash payment and a potential total...
FDA targets compounding of GLP‑1s: 30 warning letters hit telehealth firms
The U.S. Food and Drug Administration issued 30 warning letters to telehealth and compounding firms it says are marketing unapproved, misbranded compounded GLP‑1 products as equivalent to approved...
Prime to test FDA flexibility: Two‑patient gene‑editing bid for rare disease
Prime Medicine reversed course and is preparing an FDA filing seeking approval of its prime‑editing therapy for a form of chronic granulomatous disease (CGD) based primarily on data from two...
Gyre acquires Cullgen: $300M deal brings targeted protein degrader engine
Gyre Therapeutics announced an all‑stock acquisition of Cullgen valued at roughly $300 million, a deal that folds Cullgen’s targeted protein degradation (TPD) discovery engine and two...
UCB bets on TCEs: $1.1B licensing deal for Antengene’s ATG‑201
UCB agreed to license Antengene’s preclinical CD19xCD3 bispecific T‑cell engager ATG‑201 in a deal with up to $1.1 billion in milestones and roughly $80 million up front. Under terms Antengene...
FDA puts PepGen trial on partial hold — company and analysts respond
The FDA placed a partial clinical hold on PepGen’s Phase 2 trial for a rare muscle wasting disorder, citing unresolved questions in the company’s preclinical data package. The hold affects the...
BillionToOne scales: Q4 revenue surges, UnitedHealthcare in‑network deal
Molecular diagnostics company BillionToOne reported Q4 revenue that more than doubled year‑over‑year and raised full‑year 2026 guidance. Management cited new payer contracts — notably an...
Parkin gene therapy rescues dopamine neurons: Preclinical in vivo success
A research team reported that Parkin gene therapy restored dopaminergic neuron function and survival in cellular and animal Parkinson’s disease models. The study demonstrated improved neuronal...
Gene regulation cuts seizures in Dravet: zorevunersen posts dramatic trial results
A multicenter clinical program led by University College London and Great Ormond Street Hospital reported that zorevunersen, a gene‑regulation therapeutic for Dravet syndrome, produced large...
Moderna settlement ends LNP war: $950M upfront, up to $2.25B at stake
Moderna agreed to settle long-running patent litigation over lipid nanoparticle (LNP) delivery technology, resolving claims by Arbutus Biopharma and Roivant subsidiary Genevant. The company will...